Continuing Medical Education (CME) Market Report 2025: Revenues to Grow from $9.41 in 2025 to $14.6 Billion by 2030, at 9.15% CAGR
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
ZIEN Medical Technologies Achieves CE Mark
SALT LAKE CITY, Aug. 6, 2025 /PRNewswire/ -- ZIEN Medical Technologies ("ZIEN"), a portfolio company of Banner Capital, is pleased to announce achievement of its first CE Mark under the EU MDR (EU 2017/745) on behalf of its customer SAM Medical Products ( Founded in 2009 and based in Salt Lake City, ZIEN is a vertically integrated medical device contract design & manufacturing organization ("CDMO") providing product design & development, manufacturing, cost-down, packaging, sterilization, and quality & regulatory services to medical device companies. As part of ZIEN's capabilities, the ability to act as the "Legal Manufacturer (LM)" or "Manufacturer of Record (MoR)" allows ZIEN to serve as an accelerator to speed innovative technologies to the global market. With ZIEN's EU MDR and MDSAP certifications and ability to serve as LM/MoR technologies that would otherwise take a Medical Device company over 2+ years to reach certification can be brought to market in likely under a year. Combined with ZIEN's other innovative offerings such as packaging and sterilization services the overall combined cost and time savings to reach the market can be significant. SAM Medical Products is an innovator in devices targeted to serve patients undergoing emergency medical procedures. Having provided devices for fracture management, hemorrhage control, and respiratory management SAM Medical entered the Intraosseous Access Market to improve its ability to serve patients in these emergency situations. Having served patients in the USA, Canada, and other global regions SAM desired to reach patients in Europe. Through the existing relationship with ZIEN as a contract manufacturer of the IO products SAM Medical found in ZIEN an opportunity to help expand their capacity and market reach by using ZIEN to provide regulatory support as MoR for the IO product. This allows SAM Medical to focus on expanding other product introductions, and place attention on the market distribution of the IO products while ZIEN manages the ongoing regulatory and engineering support and maintenance of the IO. Kyle Sims, Director of Product Development for SAM Medical stated, "ZIEN's role as Manufacturer of Record allows us to expand our engineering and product support capacity by transitioning the regulatory and technical oversight of this strong IO product line to their team. This partnership enables our internal teams to focus on building out the broader SAM Medical portfolio and gives us a scalable path to deliver more patient solutions as we grow our market presence." Tim Nieman, CEO of ZIEN, remarked "ZIEN has for over 16 years been serving our customers as an integrator of services allowing speed to market for medical devices. The EU MDR has resulted in increased barriers to the introduction of innovative technologies, stifling technology and causing supply bottlenecks. We have seen products that can help patients either be retracted from the EU market or fail to reach the EU due to the expense and complexities of achieving CE mark. ZIEN is pleased to once again be able to help our customers break through these barriers to provide care solutions that might otherwise not reach patients. With the EU MDR and MDSAP certificates and the experienced team here at ZIEN, we are poised to be able to develop, manufacture, and distribute, products that can bring care to patients worldwide while simultaneously reducing the time and expense of doing so. We believe that this service offering reduces the time to global market for a product by up to 2 years and by more than $100,000. Our partnership with SAM Medical allows us to bring the benefits of the SAM Medical IO products to patients in the EU that have to date been unable to have access to this product." Media Contact: Tim Nieman, View original content to download multimedia: SOURCE ZIEN Medical Technologies LLC Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
FTC moves to block Edwards' JenaValve acquisition
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. The Federal Trade Commission has moved to block Edwards Lifesciences' planned acquisition of JenaValve Technology, citing concerns that the deal threatens to reduce competition in the market for devices to treat aortic regurgitation. The agency alleged that over two days in July 2024, Edwards signed agreements to acquire both JenaValve and JC Medical, the two leading companies competing to bring transcatheter aortic valve replacement devices to market to treat the potentially fatal heart condition. Edwards closed the acquisition of JC Medical in August 2024. The FTC said Edwards' proposed $945 million acquisition of JenaValve would combine the only two companies conducting U.S. clinical trials for a TAVR aortic regurgitation, or TAVR-AR, device. 'The deal threatens to reduce competition in the TAVR-AR market, likely resulting in reduced innovation, diminished product quality, and potentially increased prices for consumers,' the agency stated in a federal court complaint. The commission voted 3-0 to issue an administrative complaint and seek a temporary restraining order and a preliminary injunction to halt the transaction pending an administrative proceeding. The complaint and injunction request were filed in the U.S. District Court for the District of Columbia. JenaValve is poised to become the first company to bring a TAVR-AR device, called Trilogy, to the U.S. market, the FTC said. Food and Drug Administration approval of a TAVR-AR device by another company besides Edwards and JenaValve is not expected in the foreseeable future. 'The FTC is taking action to stop this anticompetitive deal and ensure that JenaValve and Edwards' JC Medical subsidiary continue competing to innovate, expand treatment eligibility, and keep down costs,' Daniel Guarnera, director of the FTC's Bureau of Competition, said in the agency's Wednesday statement. Edwards' stance Edwards said Wednesday that it disagrees with the FTC's decision and believes it will limit the treatment options for patients with aortic regurgitation. Edwards argued that the acquisition will actually 'accelerate the availability, adoption and continued innovation of a life-saving treatment for patients suffering from AR.' The company plans to continue to pursue regulatory approval for the deal and expects a final determination by the end of the first quarter of 2026. JenaValve also said that it remains committed to completing the transaction and is confident in the rationale for the merger and the value it will bring to patients. The company intends to join Edwards to defend the case in court. Edwards increased its forecast for 2025 adjusted earnings per share to the high end of a range of $2.45 to $2.55, up from the high end of a range of $2.40 to $2.50, to reflect the impact of the FTC's action. The company said there is no impact to revenue guidance. Edwards agreed to pay $1.2 billion combined in July 2024 to buy JenaValve and Endotronix, which makes an implantable heart failure sensor. With the Endotronix transaction completed, Edwards was expecting the JenaValve deal to close in the middle of this year. Recommended Reading Edwards shrugs off tariffs, backs 2025 profit forecast
Yahoo
2 hours ago
- Yahoo
FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine
FDA approves single-dose AJOVY® (fremanezumab-vfrm) injection for the preventive treatment of episodic migraine in children and adolescents aged 6-17 who weigh 45 kilograms or more, offering a long-awaited monthly treatment option with in-office or at-home administration1 AJOVY expands access across age groups as the first and only calcitonin gene-related peptide (CGRP) antagonist approved for pediatric episodic migraine prevention and migraine prevention in adults1 This approval marks an important step in expanding the impact of AJOVY beyond adults since its U.S. approval in 2018, and underscores Teva's ongoing efforts to advance and address neurological challenges2 PARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today that the U.S. Food and Drug Administration (FDA) has approved AJOVY for the preventive treatment of episodic migraine in children and adolescent patients aged 6-17 years who weigh 45 kilograms (99 pounds) or more. With this approval, AJOVY becomes the first and only calcitonin gene-related peptide (CGRP) antagonist indicated for the preventive treatment of episodic migraine in pediatric patients and migraine in adults, marking a meaningful advancement in expanding preventive treatment options for those living with migraine. Preventative treatment can help reduce the frequency of migraine attacks, helping children and adolescents to better manage the condition day-to-day. AJOVY is administered once a month and available for in-office or at home use, offering a treatment option that is intended to support adherence and reduce treatment burden for families.1 'Migraines are a common yet invisible condition that can severely disrupt daily life for children and adolescents, often leaving them overlooked and misunderstood,' said Chris Fox, Executive Vice President, U.S. Commercial and Innovative Franchise Lead and Head of Global Marketing Business at Teva. 'With this FDA approval, AJOVY now offers younger patients a new treatment option, addressing a long-standing gap in care and offering families added support as they navigate the challenges of this condition.' 1 in 10 children and adolescents in the U.S. suffer from migraine, one of the most common and disabling neurological conditions.3 Despite its widespread prevalence, pediatric migraine is often underrecognized and undertreated, contributing to missed school days, difficulties with schoolwork, and disrupted social activities.4 "Pediatric migraine is a complex condition that can significantly impact a child's daily life, from school performance to emotional well-being," said Dr. Jennifer McVige, MD, MA, Pediatric Neurologist at the DENT Neurologic Institute. 'Having an FDA-approved treatment like AJOVY offers an important option, providing a targeted approach to preventive treatment for episodic migraine that can help reduce the frequency of attacks in younger patients and help clinicians manage this often-overlooked condition.' Building on its established success in adult patients since its U.S. approval in 2018, this expanded indication strengthens Teva's commitment to broadening access to neuroscience therapies across age groups.2 AJOVY continues to demonstrate efficacy in addressing the underlying biology of migraine and now provides a treatment pathway for a patient population with historically limited preventive options. About MigraineMigraine attacks cause disabling pain, nausea, vomiting and sensitivities to light and sound, resulting in serious effects on the ability to complete daily tasks.5 Migraine can cause significant disability in children and adolescents, leading to absence from school, impaired educational performance and missed social activities.3 About AJOVYAJOVY is indicated for preventive treatment of migraine in adults and episodic migraine in children and adolescent patients aged 6-17 years who weigh 45 kilograms (99 pounds) or more. AJOVY is available as a 225 mg/1.5 mL single dose injection in a pre-filled autoinjector or in a pre-filled syringe. AJOVY can be administered either by a healthcare professional or at home by a patient or caregiver. No starting dose is required to begin treatment. For full prescribing information, visit INDICATION AND USAGE AJOVY is indicated for: the preventive treatment of migraine in adults, and the preventive treatment of episodic migraine in pediatric patients who are 6 to 17 years of age and who weigh 45 kg or more. IMPORTANT SAFETY INFORMATION Contraindications: AJOVY is contraindicated in patients with serious hypersensitivity to fremanezumab-vfrm or to any of the excipients. Reactions have included anaphylaxis and angioedema. Hypersensitivity Reactions: Hypersensitivity reactions, including rash, pruritus, drug hypersensitivity, and urticaria were reported with AJOVY in clinical trials. Most reactions were mild to moderate, but some led to discontinuation or required corticosteroid treatment. Most reactions were reported from within hours to one month after administration. Cases of anaphylaxis and angioedema have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing AJOVY and institute appropriate therapy. Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of CGRP antagonists, including AJOVY, in the postmarketing setting. Monitor patients treated with AJOVY for new-onset hypertension or worsening of pre-existing hypertension, and consider whether discontinuation of AJOVY is warranted. Raynaud's Phenomenon: Development of Raynaud's phenomenon and recurrence or worsening of pre-existing Raynaud's phenomenon have been reported in the postmarketing setting following the use of CGRP antagonists, including AJOVY. Many of the cases reported serious outcomes, including hospitalizations and disability, generally related to debilitating pain. AJOVY should be discontinued if signs or symptoms of Raynaud's phenomenon develop. Patients with a history of Raynaud's phenomenon should be monitored for, and informed about the possibility of, worsening or recurrence of signs and symptoms. Adverse Reactions: The most common adverse reactions in clinical trials (≥5% and greater than placebo) were injection site reactions. Please click here for full U.S. Prescribing Information for AJOVY (fremanezumab-vfrm) injection. About TevaTeva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva's commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients' needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as 'should,' 'expect,' 'anticipate,' 'estimate,' 'target,' 'may,' 'project,' 'guidance,' 'intend,' 'plan,' 'believe' and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop and commercialize AJOVY (fremanezumab) for the prevention of episodic migraine in children and adolescents; our ability to successfully compete in the marketplace including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development; and other factors discussed in this press release, in our Quarterly Report on Form 10-Q for the second quarter of 2025 and in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the section captioned 'Risk Factors.' Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements. AJOVY (fremanezumab-vfrm) injection, for subcutaneous use. Current Prescribing Information. Parsippany, NJ. Teva Neuroscience, Inc. Data on file. Parsippany, NJ: Teva Neuroscience, Inc. Al Khalili Y, Asuncion RMD, Chopra P. Migraine Headache in Childhood. [Updated 2023 Mar 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: Pediatric Migraine, An Update. Greene, Kaitlin. et al; Neurology clinics, Volume 37, Issue 4, 815-833. August 31, 2019. Jaimie D Steinmetz, Katrin Seeher, Nicoline Schiess, Emma Nichols, Bochen Cao, Chiara Servili, Vanessa Cavallera, Christopher J L Murray, Kanyin Liane Ong, Valery L Feigin, Theo Vos, and Tarun Dua on behalf of the GBD network. Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Neurol. (in press). Teva Media Inquiries:TevaCommunicationsNorthAmerica@ Teva Investor Relations InquiresTevaIR@
